Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis gets access to UPenn's immunotherapies and technology

Executive Summary

Novartis AG has teamed up with the University of Pennsylvania to develop cellular immunotherapies for cancer. The Big Pharma gets exclusive rights to UPenn’s chimeric antigen receptor technologies as well as the drug candidates that result from its use, including CART19 which targets the CD19 protein. It was discovered by the university's Carl June, MD, and is expected to start Phase II in Q4 2012.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Immuno-Oncology
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies